Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 424 participants.
Also called NCT07122401
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 424 participants
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
- Registry
-
NCT07122401
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07122401. Randomized; quadruple masking; primary purpose treatment. Start 2025-09-30 (actual); primary completion 2026-11-26 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism
- Condition
- Secondary Hyperparathyroidism, Chronic Kidney Disease
- Intervention (Drug)
- MT1013
- Intervention (Drug)
- Cinacalcet
- Lead sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Record details
- Record id
cardio:ct-nct07122401- Content hash
ee59b069a9c74bec48089e0e43ab413222f571c0d33e5e324c50b98d45c5b3c6